SHIT IS HAPPENING NOW!!!!!
On Linked in released by Paul Segal 4 hours ago
Symtomax prepares to launch their CBD oral tab
bioavailability of CBD when administered using Oral
Tab has been tested in numerous National Institutes
of Health (NIH) funded studies which discovered that
40-50% of the CBD reaches systemic circulation
where it can have effect. In comparison, other nonsmoking
forms such as edibles often deliver only
4-11% of the listed amount of active ingredients.
With superior absorption in comparison, Oral Tabs
offer patients the opportunity to benefit from
therapeutic effects at markedly reduced doses. Other
benefits over existing modes of delivery include the
reduction of adverse respiratory effects, elimination
of swallowing hazards and the elimination of
consuming unpleasant tasting oil.
Coetzee continued: “Placing the Oral Tab onto the
inside of the cheek allows for rapid absorption of the
CBD into the blood stream, and since it does not
have to be digested like oils or edibles, the products
work quickly and effectively on the area where it is
needed.” The technology is versatile, and over time
will be adapted to include additional cannabinoids as
markets permit.
In addition to presenting customers with a more
efficient product, Oral Tabs is also much more
convenient and discrete. Unlike dropper bottles, Oral
Tabs fit easily into a wallet or purse, with no mess -
making it a convenient product that can be taken on
the go.
Prominent Canadian cannabis
expert joins Symtomax
In preparation of the Oral Tab’s launch, Symtomax
has welcomed Samantha Roman, co-founder of an
early Canadian medical cannabis facility and the first
woman in the industry to complete an acquisition of
a public market company. She is currently the CEO
of Credible Cannabis, a global management
advisory, and founder of Women Leading Cannabis.
Paul Segal, Symtomax Chairman said “We are thrilled
to have Samantha join our team. We have always
consciously developed our Board with an eye
towards the future and Samantha brings a fresh
perspective and diverse skills and experiences that
will help shape the company’s long-term growth
strategy. Our Company continues to dedicate itself to
providing consumers with all natural products infused
with the highest quality CBD oil and the launch of our
Oral Tabs ensures we will have a share of this
expanding market.”
Roman announced: “I’m pleased to be associated
with the formidable team of professionals at
Symtomax as they begin delivering quality products
to patients and consumers from one of Europe’s
most highly regulated CBD markets.”
A pioneering member in the Canadian cannabis
market since 2013, Roman has worked with
companies in five continents drawing on her
education which includes a Bachelor of Science in
Nursing, and Master of Business Administration. Prior
to cannabis her professional career included leading
strategy development and business execution for
several Global 50 brand companies within global
financial services, pharmaceuticals, and medical
distribution. A discerning professional, her opinions
and insights are sought by renowned investors and
national media. She is also a dynamic panellist,
moderator and an advisor to international cannabis
science and business conferences.
The first Oral Tabs will contain 25mg of full spectrum
CBD in each sachet and will be available in 5 and 30
pack boxes in berry mint flavour with additional packet
sizes, formulations and flavours planned for later on
in the year. Symtomax have sourced numerous retail
outlets and pharmacies for the distribution of the oral
tab throughout Europe and are in further discussions
with one of Australia's major suppliers and
distributors, and a leading chain of health food shops
with over 1,300 stores in 16 countries. The Oral Tabs
will also be available soon via their online store
www.oraltabs.com. Oral Tabs is a wholly owned
subsidiary of Symtomax Lda Portugal.
On Linked in released by Paul Segal 4 hours ago
Symtomax prepares to launch their CBD oral tab
bioavailability of CBD when administered using Oral
Tab has been tested in numerous National Institutes
of Health (NIH) funded studies which discovered that
40-50% of the CBD reaches systemic circulation
where it can have effect. In comparison, other nonsmoking
forms such as edibles often deliver only
4-11% of the listed amount of active ingredients.
With superior absorption in comparison, Oral Tabs
offer patients the opportunity to benefit from
therapeutic effects at markedly reduced doses. Other
benefits over existing modes of delivery include the
reduction of adverse respiratory effects, elimination
of swallowing hazards and the elimination of
consuming unpleasant tasting oil.
Coetzee continued: “Placing the Oral Tab onto the
inside of the cheek allows for rapid absorption of the
CBD into the blood stream, and since it does not
have to be digested like oils or edibles, the products
work quickly and effectively on the area where it is
needed.” The technology is versatile, and over time
will be adapted to include additional cannabinoids as
markets permit.
In addition to presenting customers with a more
efficient product, Oral Tabs is also much more
convenient and discrete. Unlike dropper bottles, Oral
Tabs fit easily into a wallet or purse, with no mess -
making it a convenient product that can be taken on
the go.
Prominent Canadian cannabis
expert joins Symtomax
In preparation of the Oral Tab’s launch, Symtomax
has welcomed Samantha Roman, co-founder of an
early Canadian medical cannabis facility and the first
woman in the industry to complete an acquisition of
a public market company. She is currently the CEO
of Credible Cannabis, a global management
advisory, and founder of Women Leading Cannabis.
Paul Segal, Symtomax Chairman said “We are thrilled
to have Samantha join our team. We have always
consciously developed our Board with an eye
towards the future and Samantha brings a fresh
perspective and diverse skills and experiences that
will help shape the company’s long-term growth
strategy. Our Company continues to dedicate itself to
providing consumers with all natural products infused
with the highest quality CBD oil and the launch of our
Oral Tabs ensures we will have a share of this
expanding market.”
Roman announced: “I’m pleased to be associated
with the formidable team of professionals at
Symtomax as they begin delivering quality products
to patients and consumers from one of Europe’s
most highly regulated CBD markets.”
A pioneering member in the Canadian cannabis
market since 2013, Roman has worked with
companies in five continents drawing on her
education which includes a Bachelor of Science in
Nursing, and Master of Business Administration. Prior
to cannabis her professional career included leading
strategy development and business execution for
several Global 50 brand companies within global
financial services, pharmaceuticals, and medical
distribution. A discerning professional, her opinions
and insights are sought by renowned investors and
national media. She is also a dynamic panellist,
moderator and an advisor to international cannabis
science and business conferences.
The first Oral Tabs will contain 25mg of full spectrum
CBD in each sachet and will be available in 5 and 30
pack boxes in berry mint flavour with additional packet
sizes, formulations and flavours planned for later on
in the year. Symtomax have sourced numerous retail
outlets and pharmacies for the distribution of the oral
tab throughout Europe and are in further discussions
with one of Australia's major suppliers and
distributors, and a leading chain of health food shops
with over 1,300 stores in 16 countries. The Oral Tabs
will also be available soon via their online store
www.oraltabs.com. Oral Tabs is a wholly owned
subsidiary of Symtomax Lda Portugal.
